About Helsinn
Helsinn is a company based in Lugano (Switzerland) founded in 1976 by Gabriele Braglia. The company has 103 employees as of December 31, 2021. Helsinn has completed 1 acquisition, including Sapphire Therapeutics. Helsinn offers products and services including AKYNZEO® and ALOXI®. Helsinn operates in a competitive market with competitors including Aster Insights, Abogen Biosciences, OnCusp, CancerVax and Linical, among others.
- Headquarter Lugano, Switzerland
- Employees 103 as on 31 Dec, 2021
- Founders Gabriele Braglia
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Helsinn Therapeutics U.S., Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
103
as on Dec 31, 2021
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Helsinn
Helsinn offers a comprehensive portfolio of products and services, including AKYNZEO® and ALOXI®.
Medication for preventing chemotherapy-induced nausea
Treatment for nausea and vomiting in cancer therapy
People of Helsinn
Unlock access to complete
Sales and Marketing
14 people
Software Development Team
8 people
Product Management Team
3 people
Leadership Team
3 people
Human Resources and Administration
3 people
Strategic Team
1 people
Environment Team
1 people
Legal and Compliance
1 people
Unlock access to complete
Funding Insights of Helsinn
Investors in Helsinn
Helsinn has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Oberland Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Structured financing solutions are provided for the global healthcare industry by Oberland Capital.
|
Locked | Locked | Locked |
Investor details for Helsinn
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Helsinn
Helsinn has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Sapphire Therapeutics.
Investment portfolio details for Helsinn
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Small molecule drugs are developed for metabolic and oncologic disorders.
|
Locked | Locked | 2008 | Locked |
Complete acquisition details for Helsinn
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Helsinn
Detailed financials for Helsinn
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Helsinn Comparisons
Peer comparison for Helsinn
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Helsinn
Helsinn operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aster Insights, Abogen Biosciences, OnCusp, CancerVax and Linical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Contract-based oncology clinical trial services are provided by Aster Insights.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics are developed for cancer and infectious diseases.
|
|
| Locked | Locked | Locked |
CRO offering clinical development services for oncology drugs
|
|
| Locked | Locked | Locked |
Cancer vaccine research and development is conducted by CancerVax.
|
|
| Locked | Locked | Locked |
Full-service CRO operations are conducted across more than 20 countries.
|
Detailed competitors of Helsinn
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Helsinn
Complete news archive for Helsinn
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Helsinn
Helsinn was founded in 1976 and raised its 1st funding round 47 years after it was founded.
Helsinn is headquartered in Lugano, Switzerland. It is registered at Lugano, Ticino, Switzerland.
As of Dec 31, 2021, the latest employee count at Helsinn is 103.
CDMO focused on developing, manufacturing, and commercialising oncology therapeutics. The company recognized for its leadership in cancer supportive care, particularly in managing side effects of cancer therapies such as chemotherapy-induced nausea and vomiting. It portfolio extends to products that improve the quality of life for patients with chronic diseases.
Helsinn offers AKYNZEO® and ALOXI®.
Helsinn has made 1 acquisition, including Sapphire Therapeutics.
Helsinn has 1 investor. Key investors include Oberland Capital.